[
  {
    "ts": null,
    "headline": "Columbia Dividend Opportunity Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Opportunity Fund amid tech and energy drags. Discover how AI picks boosted returns.",
    "url": "https://finnhub.io/api/news?id=bdba0853d155b8623eb3f99a979eabcc0975400b3ed2336c660f98498d136507",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755546000,
      "headline": "Columbia Dividend Opportunity Fund Q2 2025 Commentary",
      "id": 136413620,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223505840/image_2223505840.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Opportunity Fund amid tech and energy drags. Discover how AI picks boosted returns.\n",
      "url": "https://finnhub.io/api/news?id=bdba0853d155b8623eb3f99a979eabcc0975400b3ed2336c660f98498d136507"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Dividend Income Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Income Fund amid tech and healthcare headwinds. See how quality stocks remain central.",
    "url": "https://finnhub.io/api/news?id=abdcfc7414c024b4a1ef96ab2faac9bbdfb29f442859ed22402764565c78c6b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755545400,
      "headline": "Columbia Dividend Income Fund Q2 2025 Commentary",
      "id": 136413574,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206196350/image_2206196350.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports Q2 underperformance for its Dividend Income Fund amid tech and healthcare headwinds. See how quality stocks remain central.\n",
      "url": "https://finnhub.io/api/news?id=abdcfc7414c024b4a1ef96ab2faac9bbdfb29f442859ed22402764565c78c6b5"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Disciplined Value Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedle Investments reports strong Q2 gains for its Disciplined Value Fund, driven by smart stock selection. Explore how their model adds value.",
    "url": "https://finnhub.io/api/news?id=92118630920b7b8f326e0a2335231683fbee1b7c90edf184e11c1a45c94fbaab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755544500,
      "headline": "Columbia Disciplined Value Fund Q2 2025 Commentary",
      "id": 136413346,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197475598/image_2197475598.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedle Investments reports strong Q2 gains for its Disciplined Value Fund, driven by smart stock selection. Explore how their model adds value.",
      "url": "https://finnhub.io/api/news?id=92118630920b7b8f326e0a2335231683fbee1b7c90edf184e11c1a45c94fbaab"
    }
  },
  {
    "ts": null,
    "headline": "FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb",
    "summary": "RUTHERFORD, Calif., August 18, 2025--The 31st One Mind Music Festival on September 13, 2025 will be hosted at Staglin Family Vineyard in Rutherford, CA. The day-long festival, presented by Bank of America and Bristol Myers Squibb, offers a unique blend of world-class wine tasting, culinary excellence, and groundbreaking science, all set against the stunning backdrop of Napa Valley.",
    "url": "https://finnhub.io/api/news?id=b97d78122134b95bf72fc9a261e66edec8758fd44d39605f88dae61f514d25a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755533340,
      "headline": "FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb",
      "id": 136408825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "RUTHERFORD, Calif., August 18, 2025--The 31st One Mind Music Festival on September 13, 2025 will be hosted at Staglin Family Vineyard in Rutherford, CA. The day-long festival, presented by Bank of America and Bristol Myers Squibb, offers a unique blend of world-class wine tasting, culinary excellence, and groundbreaking science, all set against the stunning backdrop of Napa Valley.",
      "url": "https://finnhub.io/api/news?id=b97d78122134b95bf72fc9a261e66edec8758fd44d39605f88dae61f514d25a8"
    }
  },
  {
    "ts": null,
    "headline": "Macquarie Growth And Income Fund Q1 2025 Commentary",
    "summary": "For 2Q25, Macquarie Growth and Income Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 1000Â® Value Index.",
    "url": "https://finnhub.io/api/news?id=06a97919fbe7ae2f8b32cc1dcd6e9b0ae935a9133dfb5580bc45e6eda5be2045",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755519780,
      "headline": "Macquarie Growth And Income Fund Q1 2025 Commentary",
      "id": 136407703,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190009797/image_2190009797.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "For 2Q25, Macquarie Growth and Income Fund Institutional Class shares outperformed the Fundâs benchmark, the Russell 1000Â® Value Index.",
      "url": "https://finnhub.io/api/news?id=06a97919fbe7ae2f8b32cc1dcd6e9b0ae935a9133dfb5580bc45e6eda5be2045"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific",
    "summary": "Zacks spotlights Lowe's, Bristol Myers, Marvell, and Kewaunee Scientific as earnings, strategy, and acquisitions shape growth outlooks.",
    "url": "https://finnhub.io/api/news?id=6f8d0eeb3d855af3fb00a1d990b739e86ecd6f731e5f77a2fb6badd0fa765ba0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755513360,
      "headline": "The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific",
      "id": 136408684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Zacks spotlights Lowe's, Bristol Myers, Marvell, and Kewaunee Scientific as earnings, strategy, and acquisitions shape growth outlooks.",
      "url": "https://finnhub.io/api/news?id=6f8d0eeb3d855af3fb00a1d990b739e86ecd6f731e5f77a2fb6badd0fa765ba0"
    }
  },
  {
    "ts": null,
    "headline": "Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer",
    "summary": "SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an",
    "url": "https://finnhub.io/api/news?id=d14550bd50fe94fa906c2adc6c58fbbdef294586a55e9cdd6ae1f8971404d117",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755511200,
      "headline": "Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer",
      "id": 136408828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an",
      "url": "https://finnhub.io/api/news?id=d14550bd50fe94fa906c2adc6c58fbbdef294586a55e9cdd6ae1f8971404d117"
    }
  },
  {
    "ts": null,
    "headline": "Biopharma layoffs rise as drugmakers tighten belts and reorganize",
    "summary": "Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.",
    "url": "https://finnhub.io/api/news?id=fa88c71760b7feca0edda9fb50b38c77ec15f2f2a7db74b89a3e4af089ec1731",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755503918,
      "headline": "Biopharma layoffs rise as drugmakers tighten belts and reorganize",
      "id": 136408498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.",
      "url": "https://finnhub.io/api/news?id=fa88c71760b7feca0edda9fb50b38c77ec15f2f2a7db74b89a3e4af089ec1731"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Disciplined Core Fund Q2 2025 Commentary",
    "summary": "Columbia Threadneedleâs Disciplined Core Fund returned 9.54% in Q2 2025, led by AI-fueled tech picks. Discover how stock selection shaped performance.",
    "url": "https://finnhub.io/api/news?id=14004334a33338f0bff7880fa3dda2ae5a8d7c6c6ae5c28bc538690f26cafcac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755496800,
      "headline": "Columbia Disciplined Core Fund Q2 2025 Commentary",
      "id": 136406256,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1469297427/image_1469297427.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Columbia Threadneedleâs Disciplined Core Fund returned 9.54% in Q2 2025, led by AI-fueled tech picks. Discover how stock selection shaped performance.",
      "url": "https://finnhub.io/api/news?id=14004334a33338f0bff7880fa3dda2ae5a8d7c6c6ae5c28bc538690f26cafcac"
    }
  }
]